CAL
EGRX

Capital Advisors Ltd’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Capital Advisors Ltd’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-149
Closed -$1K – 1636
2024
Q3 		$1K Hold
149
– – ﹤0.01% 1336
2024
Q2 		$1K Sell
149
-26
-15% -$113 ﹤0.01% 1335
2024
Q1 		$1K Buy
+175
New +$960 ﹤0.01% 1312

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Capital Advisors Ltd's EGRX Position: Q4 2024 in Review

Capital Advisors Ltd sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 149 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in EGRX in Q1 2024 and held it in 3 quarters. The position peaked at $1K in Q3 2024. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Capital Advisors Ltd reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Capital Advisors Ltd sold 149 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $1K.
  • Capital Advisors Ltd first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2024 and held it in 3 quarters.
  • Capital Advisors Ltd's Eagle Pharmaceuticals, Inc. position peaked at $1K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Capital Advisors Ltd's 13F filing for Q4 2024, filed 4 Feb 2025.